T cell co-receptor clustering for cancer treatment

This technology is a SLAMF6 bispecific antibody to enhance T-cell activation through compartmentalization that can be used for tumor treatments.

Unmet Need: Safe and targeted T-cell activation for cancer immunotherapy

Current cancer immunotherapies involve inhibition of checkpoint receptors between T cells and tumor cells. These treatments present limitations such as patient unresponsiveness and immune-related adverse events. There is a need to develop highly targeted therapies that reduce the risk of non-specific T-cell activation. Clustering receptors in specific locations on the cell surface is key to enhance T-cell activity.

The Technology: Bispecific co-receptor antibodies for targeted T-cell activation

This technology describes bispecific monoclonal antibodies that target SLAMF6 co-receptors. SLAMF6 is required for T-cell activation, and its location on the cell surface can affect T-cell functions. By promoting or inhibiting SLAMF6 with different TCR complex such as CD3 or CD45, T-cell activation is enhanced. Additionally, antibodies targeting co-receptor functions reduce the risk of activating resting T-cells, minimizing off-target effects.

This technology has been validated with human cells.

Applications:

• Immunotherapy for cancer treatment
• Research model for studying co-receptor clustering and T cell activation
• Targeted T-cell therapeutic intervention
• Immunomodulation therapy

Advantages:

• Precise compartmentalization
• Avoids non-specific T-cell activation
• Reduced risk of adverse inflammatory immune related effects
• Compatibility with existing therapies

Lead Inventor:

Adam Mor, M.D. Ph.D.

Patent Information:

Patent Pending

Related Publications:

• Gartshteyn Y, Askanase AD, Song R, Bukhari S, Dragovich M, Adam K, Mor A. “SLAMF6 compartmentalization enhances T cell functions.” Life Sci Alliance. 2022 Dec 8; 6(2): e202201533.

Tech Ventures Reference:

• IR CU22398

• Licensing Contact: Cynthia Lang